--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-23-165305" form_type: "8-K" ticker: "TCRT" cik: "0001107421" company_name: "Alaunos Therapeutics, Inc." filed_at: "2023-06-12T23:59:59+00:00" generated_at: "2026-06-14T02:39:59.781101+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.6 calibrated_materiality_score: 0.6 confidence: "high" source: SEC EDGAR --- # Alaunos Therapeutics stockholders approve reverse stock split and increase in authorized shares ## Summary - Stockholders approved a reverse stock split at a ratio of 1-for-5 to 1-for-15, at Board discretion (141.4M for, 38.5M against). - Authorized common shares increased from 420M to 520M (138.3M for, 41.9M against). - All seven director nominees elected; RSM US LLP ratified as independent auditor for FY2023 (165.4M for). - Advisory say-on-pay approved (85.9M for); one-year frequency selected for future advisory votes (94.4M for). ## SEC filing metadata - accession: 0001193125-23-165305 - form_type: 8-K - ticker: TCRT - cik: 0001107421 - company_name: Alaunos Therapeutics, Inc. - filed_at: 2023-06-12T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.6 - calibrated_materiality_score: 0.6 - confidence: high - sec_items: 3.03, 5.07, 5.03, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000119312523165305/0001193125-23-165305-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000119312523165305/d451080d8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-23-165305 - JSON: https://secwatch.observer/filing/0001193125-23-165305.json - Plain text: https://secwatch.observer/filing/0001193125-23-165305.txt ## Key facts - Governance Changes Alaunos Therapeutics, Inc.: Increased authorized shares of common stock from 420,000,000 to 520,000,000 (effective 2023-06-12). - Change: charter amendment - Effective: 2023-06-12 source text: the Company’s stockholders voted on and approved an amendment (the “Amendment”) to the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”) to increase the number of authorized shares of common stock from 420,000,000 shares to 520,000,000 shares. evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312523165305/0001193125-23-165305-index.htm - Shareholder Votes Alaunos Therapeutics, Inc. shareholders approved Advisory vote on executive compensation at the 2023-06-06 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2023-06-06 source text: For Against Abstain Broker Non-Votes 85,893,572 20,980,848 1,948,700 72,019,091 evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312523165305/0001193125-23-165305-index.htm - Shareholder Votes Alaunos Therapeutics, Inc. shareholders approved Approval of amendment and restatement of Certificate of Incorporation to effect a reverse stock split at ratio between 1-for-5 and 1-for-15 at the 2023-06-06 meeting. - Proposal: reverse split - Outcome: passed - Meeting: 2023-06-06 source text: For Against Abstain Broker Non-Votes 141,445,911 38,471,417 924,883 — evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312523165305/0001193125-23-165305-index.htm - Shareholder Votes Alaunos Therapeutics, Inc. shareholders approved Adjournment proposal to permit further solicitation if needed for Proposals 5 and 6 at the 2023-06-06 meeting. - Outcome: passed - Meeting: 2023-06-06 source text: For Against Abstain Broker Non-Votes 144,264,709 34,642,989 1,934,513 — evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312523165305/0001193125-23-165305-index.htm - Shareholder Votes Alaunos Therapeutics, Inc. shareholders approved Approval of amendment to Certificate of Incorporation to increase authorized shares of common stock from 420,000,000 to 520,000,000 at the 2023-06-06 meeting. - Proposal: charter amendment - Outcome: passed - Meeting: 2023-06-06 source text: Proposal 6 - Approval of Amendment of the Certificate of Incorporation evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312523165305/0001193125-23-165305-index.htm - Shareholder Votes Alaunos Therapeutics, Inc. shareholders approved Ratification of RSM US LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-06 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-06-06 source text: For Against Abstain Broker Non-Votes 165,357,175 14,209,546 1,275,490 — evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312523165305/0001193125-23-165305-index.htm - Shareholder Votes Alaunos Therapeutics, Inc. shareholders approved Election of Directors at the 2023-06-06 meeting. - Proposal: director election - Outcome: passed - Meeting: 2023-06-06 source text: Proposal 1 - Election of Directors The Company’s stockholders elected all seven persons listed below as directors evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312523165305/0001193125-23-165305-index.htm - Shareholder Votes Alaunos Therapeutics, Inc. shareholders voted on Advisory vote on frequency of say-on-pay votes at the 2023-06-06 meeting. - Proposal: say on pay frequency - Meeting: 2023-06-06 source text: One Year Two Years Three Years Abstain 94,445,383 776,719 3,126,416 10,474,602 evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312523165305/0001193125-23-165305-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.